WO2007126221A1 - Composition comprenant de l'acide ursolique et de l'acide oléanolique destinée à améliorer un traitement contre l'arthrite - Google Patents

Composition comprenant de l'acide ursolique et de l'acide oléanolique destinée à améliorer un traitement contre l'arthrite Download PDF

Info

Publication number
WO2007126221A1
WO2007126221A1 PCT/KR2007/001785 KR2007001785W WO2007126221A1 WO 2007126221 A1 WO2007126221 A1 WO 2007126221A1 KR 2007001785 W KR2007001785 W KR 2007001785W WO 2007126221 A1 WO2007126221 A1 WO 2007126221A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
oldenlandia diffusa
extract
oleanolic acid
ursolic acid
Prior art date
Application number
PCT/KR2007/001785
Other languages
English (en)
Inventor
Jeong Chan Ra
Hang Young Lee
Original Assignee
Rnl Bio Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rnl Bio Co., Ltd filed Critical Rnl Bio Co., Ltd
Priority to JP2009506406A priority Critical patent/JP2009534374A/ja
Priority to KR1020087023992A priority patent/KR101084105B1/ko
Publication of WO2007126221A1 publication Critical patent/WO2007126221A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A61K36/748—Oldenlandia or Hedyotis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/076—Poria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH

Definitions

  • the present invention relates to an anti-inflammatory or analgesic composition
  • an anti-inflammatory or analgesic composition comprising of an Oldenlandia diffusa extract, which contains ursolic acid and oleanolic acid.
  • Rheumatoid arthritis is one of typical intractable inflammatory diseases. It is an autoimmune inflammatory disease resulting from an abnormal immune reaction caused by the invasion of inflammatory cells into the articular cavity and is characterized by severe pain, deformation of joints and loss of articular function. Thus, the principle of arthritis therapy used in clinical applications aims to inhibit pain and inflammation and to minimize loss of articular function.
  • nonsteroidal anti-inflammatory drugs such as aspirin
  • oral steroid immune suppressants such as methotrexate and immuran, and the like
  • Oldenlandia diffusa is an annual plant of Hedyotis lindleyanna var. hirsuta HARA or Oldenlandia diffusa L. ROXB., a member of the family Rubiaceae and is 20-40 cm in height. The lower parts thereof grow sideways while the branches thereof split, so that the plant is tilted to one side. Also, it has a number of white multicellular hairs (Yoshida. Y. et ah, Int. J. Immunopharmacol, 19:359, 1997). Oldenlandia diffusa has a cold taste, but is non-toxic and has sweet and bitter taste.
  • stomach meridian acts on the stomach meridian, the large intestine meridian and the small intestine meridian. With respect to botanical effects, it can dissipate heat, remove poison, promote diuresis, activate blood circulation against stasis and relieve carbuncles, and thus can be used to treat various inflammations, including cough caused by pulmonary heat, tonsillitis, sore throat, appendicitis, dysentery, jaundice, uterine adnexitis and arthritis, and various cancers, including digestive system cancer, liver cancer, lung cancer, lymph cancer and throat cancer (Tong, LH. et ah, Phytochemistry, 25: 1988, 1986).
  • ursolic acid is a pentacyclic triterpenoid compound extracted from various plants, and the effects and mechanisms thereof on the treatment of arthritis are known (Miceli, N. et ah, J. Ethnopharmacol,, 97:261, 2005; Park et ai, Phytother. Res., 18:930, 2004).
  • Existing arthritis treating agents which aim to suppress pain and inflammation of affected parts and minimize loss of articular function, have excellent antiinflammatory effects, but nevertheless cause severe side effects, such as gastrointestinal tract disease.
  • methods and agents for treating arthritis using natural substances have a problem in that the anti-inflammatory effects thereof are inferior to those of the prior arthritis treatment drugs.
  • an anti-inflammatory and analgesic composition which is safe to the human body and, at the same time, alleviate painful side effects.
  • the present inventors have made many efforts to develop an antiinflammatory and analgesic composition that shows efficacy in treating pain and inflammation without risk of side effects.
  • the present inventors have found that ursolic acid and oleanolic acid, extracted from the natural substance Oldenlandia diffusa, have anti-inflammatory and analgesic effects, thereby completing the present invention.
  • the present invention relates to a pharmaceutical composition for anti-inflammation and pain relief, comprising an Oldenlandia diffusa extract, which contains ursolic acid and oleanolic acid.
  • the present invention relates to a health functional food for anti-inflammation and pain relief, comprising: an Oldenlandia diffusa extract, which contains ursolic acid and oleanolic acid; and acceptable food additives.
  • the present invention relates to a method for preparing an Oldenlandia diffusa extract for anti-inflammation and pain relief, which contains ursolic acid and oleanolic acid, the method comprising the steps of: (a) crushing Oldenlandia diffusa, extracting the crushed plant with a solvent selected from the group consisting of lower alcohol, water, lower organic acid, lower alcohol ester, lower ketone, halogenated hydrocarbon, and mixtures thereof, and then concentrating the extract; (b) adding the same amount of ethylacetate to the obtained concentrate, fractionating the solution in two steps, and then concentrating the fraction; (c) adding ethylacetate: acetone: water in a ratio of 4.25-4.75 (ethylacetate): 4.25-4.75 (acetone): 0.5-1.5 (water) to the concentrate of step (b), dissolving the mixture at a temperature of 30-60 ° C , and then storing the solution at a temperature of 1-6 °
  • FIG. 1 shows HPLC analysis results for an Oldenlandia diffusa extract according to the present invention.
  • FIG. 2 is a graph detecting inflammation by collecting an exudate in pouch and measuring the number of migrated leukocytes in the exudate after induction of acute inflammation.
  • FIG. 3 is a graphic diagram showing test results obtained by centrifuging an air- pouch exudate, collecting the supernatant and measuring the amount of PGE 2 in the supernatant.
  • FIG. 4 is a graph showing the measurements of edema in each of the right paw (A) and the left paw (B).
  • FIG. 5 is an X-ray image of the right legs of mice, taken 21 days after the induction of arthritis.
  • FIG. 6 is a graph showing test results obtained by taking an X-ray of the paw sites of the animals as described above and then performing image analysis to analyze the effect of the Oldenlandia diffusa extract on the soft tissue swelling and bone proliferation caused by arthritis.
  • FIG. 7 is a graph showing measurement results of the concentration of plasma PGE 2 in blood collected from each group, 21 days after the induction of arthritis.
  • FIG. 8 is a graph showing the evaluation results of the effects of administrating the inventive extract on sensitivity to physical stimuli after the induction of arthritis.
  • FIG. 9 is a graph showing the evaluation results of the effect of the Oldenlandia diffusa extract (OE) on sensitivity to induced thermal stimuli after the induction of arthritis.
  • OE Oldenlandia diffusa extract
  • FIG. 10 is a photograph showing the expression of the Fos protein as a pain- related neuron.
  • A is a photograph of the group administered with a vehicle
  • B is a photograph of a group administered with ibuprofen
  • C is a photograph of a group administered with the OE.
  • FIG. HA is a graph showing the number of Fos-containing neurons in the right spinal cord that comes from the chronic pain in the right paw with induced arthritis
  • FIG. HB is a graph showing the number of Fos-containing neurons in the left spinal cord, which the transfer of arthritis from the right paw to the left paw.
  • FIG. 12 is a graph showing the increase in body weight of a test group treated with the OE of the present invention.
  • An Oldenlandia diffusa extract according to the present invention can be prepared by the following steps: (1) crushing Oldenlandia diffusa, extracting the crushed plant with a solvent selected from the group consisting of lower alcohol, water, lower organic acid, lower alcohol ester, lower ketone, halogenated hydrocarbon, and mixtures thereof, and then concentrating the extract; (2) adding the same amount of ethylacetate to the obtained concentrate, fractionating the solution in two steps, and then concentrating the fraction; (3) adding ethylacetate: acetone: water in a ratio of 4.25-4.75 (ethylacetate): 4.25-4.75 (acetone): 0.5-1.5 (water) to the concentrate of step (2), dissolving the mixture at a temperature of 30-60 ° C , and then storing the solution at a temperature of 1-6 ° C to produce a precipitate; and (4) collecting the extract that contains ursolic acid and oleanolic acid, from the precipitate.
  • a solvent selected from the group
  • the lower alcohol, used in step 1 can be methanol, ethanol, propanol, butanol and the like.
  • the lower organic acid can also be acetic acid, propionic acid, succinic acid, adipic acid and the like.
  • methylacetate, ethylacetate and the like may be used, and acetone, methyl ethyl ketone and the like may be used in place of the lower ketone.
  • the described method for preparing the Oldenlandia diffusa extract shows that high yields of compounds having excellent effects on anti-inflammation or pain relief can be obtained from Oldenlandia diffusa through a relatively simple process.
  • the Oldenlandia diffusa extract according to the present invention shows anti- inflammatory and analgesic effects in an air pouch model of acute inflammatory induced by zymosan and an animal model having chronic arthritis induced by Freund's adjuvant.
  • the air pouch inflammatory model induced by zymosan shows pathological symptoms similar to various inflammatory reactions appearing in arthritis patients, and thus is widely used in the assessment of effects on arthritis and in studies on mechanisms associated therewith.
  • an air pouch test was first performed to verify the anti-inflammatory effect of the Oldenlandia diffusa extract at various doses.
  • the Oldenlandia diffusa extract effectively inhibited leukocyte migration into the air pouch, and at a dose of 50 mg/kg, the highest anti-inflammatory effect of the extract could be observed. Also, at a dose of 50 mg/kg, the extract effectively inhibited the PGE 2 concentration of exudate in the air pouch, which is known to increase due to inflammatory reactions.
  • the administration of the composition according to the present invention showed an anti-inflammatory and analgesic effect similar to that of ibuprofen used as a positive control group.
  • the results of x-ray image analysis revealed that the inventive composition had an excellent effect on the inhibition of new bone proliferation.
  • thermal hyperalgesia on physical stimulation and thermal stimulation it could be seen that the inventive composition showed an excellent analgesic effect.
  • the inventive composition significantly reduced the number of Fos protein-containing neurons expressed in the spinal cord by peripheral pain, compared to a negative control group (vehicle).
  • the present invention provides a pharmaceutical composition for anti- inflammation and pain relief, comprising an Oldenlandia diffusa extract, which contains ursolic acid and oleanolic acid.
  • the content of ursolic acid and oleanolic acid in the Oldenlandia diffusa extract is preferably 80-95 wt%, and the ratio of ursolic acid: oleanolic acid is preferably 1 : 0.05-0.6.
  • the Oldenlandia diffusa extract having this content ratio has an excellent effect on anti-inflammation or pain relief compared to the case of using ursolic acid or oleanolic acid alone. This is considered to be attributable to the synergy effect of ursolic acid and oleanolic acid.
  • the pharmaceutical composition according to the present invention may additionally comprise at least one herbal extract selected from the group consisting of Inonotus obliquus, Phellinus linteus, Coriolus versicolor, Paecilomyces japonica, Cordyceps Militaris, Hericium erinaceum, Porta cocos, Agaricus, Fomitella fraxinea, Grifola frondosa, Grifola umbellate, Fomes fomentarius, Pleurotus ostreatus, Flammulina velutipes, Lentinus edodes, Agaricus blazei, Armillariella mellea, Russula virescens, Tricholoma matsutake and Auricularia auricula extracts.
  • the pharmaceutical composition according to the present invention may be formulated together with at least one drug selected from the group consisting of anti-histamine drugs, anti- inflammatory drugs, anti-cancer drugs and antibiotic drugs.
  • the anti-histamine drug which can be used in the present invention, is a drug antagonizing the action of histamine which is the cause of allergic disease, and can block the possibility that the inventive composition can cause allergic disease.
  • the anti-inflammatory drug which can be used in the present invention, refers to a drug that alleviates inflammation, and when the anti-inflammatory drug is added to the inventive composition, the anti-inflammatory effect of the composition can be maximized.
  • the anti-cancer drug is a general term for chemotherapeutic drugs which are used for the treatment of malignant tumors, and the antibiotic drug is a metabolite produced by a microorganism and refers to a substance which either inhibits the growth of other microorganisms or kills other microorganisms with small amount thereof.
  • composition of the present invention can also be used in the form of a pharmaceutically acceptable salt thereof. Also, it can be used alone or in combination with other pharmaceutically active compounds.
  • the anti-inflammatory and analgesic composition according to the present invention can be used by formulating in the form of oral formulations, such as powders, granules, tablets, capsules, suspensions, emulsions, syrups and aerosols, agents for external application, suppositories and sterile injectable solutions according to any conventional method known in the art.
  • oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups and aerosols, agents for external application, suppositories and sterile injectable solutions according to any conventional method known in the art.
  • Examples of carriers, excipients and diluents, which can be included in a composition comprising the anti-inflammatory and analgesic composition may include lactose, dextrose, sucrose, sorbitol, mannitol, starch, xylitol, erythritol, maltitol, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
  • inventive composition can be formulated using conventional diluents or excipients, including fillers, extenders, binders, wetting agents, disintegrants and surfactants.
  • solid formulations for oral administration include tablets, pills, powders, granules and capsules. These solid formulations are prepared by mixing one or more suitable excipients such as starch, calcium carbonate, sucrose, lactose, or gelatine. Except for the simple excipients, lubricants, for example, magnesium stearate, talc, etc, can be used.
  • Liquid formulations for oral administrations are suspensions, solutions, emulsions and syrups, and the abovementioned formulations can include various excipients such as wetting agents, sweeteners, aromatics and preservatives in addition to generally used simple diluents such as water and liquid paraffin.
  • Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried formulations and suppositories.
  • non-aqueous solutions and suspensions propylene glycol, polyethylene glycol, vegetable oil like olive oil, injectable ester like ethyloleate, etc may be used.
  • As suppositories witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerinated gelatin, etc can be used.
  • a preferred dose of the inventive composition depends on the condition and weight of a patient being treated, the severity of disease, drug type, and administration route and period, but may be selected properly by a person skilled in the art. However, it is preferred to administer the composition of the present invention at a dose of 0.0001-100 mg/kg/day, and more preferably 0.001-100 mg/kg/day. The administration may be done once or several times a day. Said dose does not limit, in any way, the scope of the present invention.
  • the anti-inflammatory and analgesic composition of the present invention may be administered via various routes to mammals, such as rats, mice, domestic animals, and humans. It is anticipated that all administration methods can be allowed. For example, it can be administered through oral, rectal, intravenous, intramuscular, hypodermic, intrauterine, epidural or intracerebroventricular injections.
  • the present invention provides a health functional food for anti- inflammation and pain relief, comprising: an Oldenlandia diffusa extract, which contains ursolic acid and oleanolic acid; and acceptable food additives.
  • the content of ursolic acid and oleanolic acid in the Oldenlandia diffusa extract is preferably 80-95 wt%, and the ratio of ursolic acid: oleanolic acid is preferably 1 : 0.05-0.6.
  • the health functional food according to the present invention may additionally comprise at least one herbal extract selected from the group consisting of Inonotus obliquus, Phellinus linteus, Coriolus versicolor, Paecilomyces japonica, Cordyceps Militaris, Hericium erinaceum, Poria cocos, Agaricus, Fomitella fraxinea, Grifola frondosa, Grifola umbellate, Fomes fomentarius, Pleurotus ostreatus, Flammulina velutipes, Lentinus edodes, Agaricus blazei, Armillariella mellea, Russula virescens, Tricholoma matsutake and Auricularia auricula extracts.
  • At least one herbal extract selected from the group consisting of Inonotus obliquus, Phellinus linteus, Coriolus versicolor, Paecilomyces japonica
  • the anti-inflammatory or analgesic composition of the present invention can be used as a main component of food, an additive or a supplement in the preparation of functional foods or health supplement foods.
  • the term "functional food” refers to a food obtained by adding the inventive composition to general food so as to improve the functionalities of the general food. Functionalities can be broadly divided into physical properties and physiological functionalities, and when the inventive composition is added to general food, the physical properties and physiological functionalities of the general food will be improved. In the present invention, such food having improved function is generally defined as "functional food”.
  • the anti-inflammatory or analgesic function of the present invention can be used to prepare health functional foods for anti-inflammation or pain relief.
  • the inventive composition can also be applied for the preparation of dietary supplement for arthritis patients.
  • the composition of the present invention may contain food additives, including various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring agents and enhancers (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH control agents, stabilizers, preservatives, glycerins, alcohols, carbonating agents for carbonated beverage, and so on.
  • the composition of the present invention may contain natural fruit juices and fruit pulps for the production of fruit juice drinks and vegetable drinks. These ingredients can be used independently or in combination. The proportion of these additives is not so critical, but can be generally selected from the range of 0.01 to 20 parts by weight per 100 parts by weight of the inventive composition for anti-inflammation and pain relief.
  • FIG. 1 shows the HPLC analysis results for the Oldenlandia diffusa extract according to the present invention. For the HPLC analysis, 2 mg of the Oldenlandia diffusa extract was added and dissolved in 1 ml of 100% methanol.
  • Example 2 anti-inflammatory and analgesic effects on acute air pouch inflammation in animal model
  • ICR mice each weighing 25 g; the Hallym experimental animal center, Korea
  • zymosan yeast cell wall
  • ICR mice (each weighing 25 g; the Hallym experimental animal center, Korea) were selected and administered with drugs described in Table 1 below.
  • 10 animals were administered only with a vehicle, 10 animals were administered with ibuprofen, and the remaining 50 animals were administered with the Oldenlandia diffusa extract prepared in Example 1.
  • the OE contained ursorlic acid and oleanolic acid, at doses of 12.5 mg/kg, 25 mg/kg, 50 mg/kg, 100 mg/kg and 200 mg/kg, each of the doses being for ten animals.
  • yeast cell wall was injected at a dose of 500 ⁇ l to induce acute inflammation.
  • the OE showed the highest anti-inflammatory effect at a dose of 50 mg/kg, and this anti-inflammatory effect was similar to an anti-inflammatory effect observed in the ibuprofen- treated group (100 mg/kg) as a control group.
  • Example 3 Anti-inflammatory and analgesic effects on chronic arthritis in animal model
  • Sprague- Dawley rats (each weighing 180 g; the experimental animal institute of Seoul National University, Korea) were used. They were kept under a 12-hr dark/ 12-hr light cycle at constant temperature and humidity and given food and water ad libitum.
  • Each of the above-described vehicle, ibuprofen and OE was administered using a zonde at a dose of 50 ⁇ /10 g.
  • an air pouch was made to form an artificial independent space, and 50 ⁇ i of Freund's adjuvant ⁇ Mycobacterium butyricium suspended in mineral oil at a concentration of 20 mg/ml) prepared for induction of arthritis was injected into the paw of each rat.
  • the drugs were administered for a period from day 12 to day 21 after the induction of arthritis.
  • the following items were measured as indeces of pain and inflammation caused by arthritis, and before the induction of arthritis, a baseline value (day 0) was measured.
  • the test was terminated at day 21 post induction of arthritis .
  • FIG. 5 is an X-ray image of the right legs of mice, taken 21 days after the induction of arthritis. From FIG. 5, it could be seen that group (B) administered with 100 mg/kg of ibuprofen and group (C) administered with 50 mg/kg of the
  • FIG. 6 is a graphic diagram showing test results obtained by taking an X-ray of the animals' paws as described above and then performing image analysis to analyze the effect of the drugs on the soft tissue swelling and bone proliferation caused by arthritis.
  • FIG. 6 it could be seen that, in the case of the right legs of the test animal group administered orally with the OE, the soft tissue swelling and bone proliferation caused by arthritis were significantly inhibited. Moreover, it could be seen that bone proliferation in the left legs, caused by a secondary inflammatory reaction, was also reduced due to the administration of the OE. Particularly, it could be seen that the OE had an excellent effect against bone proliferation, which was similar to an inhibitory effect observed in the ibuprofen- treated group as a drug control group.
  • the OE showed an excellent analgesic effect compared to ibuprofen as a positive control drug. Putting the above results together, it could be found that the OE, which contains ursorlic acid and oleanolic acid, had an excellent analgesic effect against pain caused by physical stimuli.
  • Rats were accommodated in a plastic chamber on a glass surface for 5 minutes, and then stimulated with radiant heat while focusing below the glass surface coming in contact with the soles of their paws.
  • Withdrawal latency (sec) the time for rats to show a withdrawal response, was measured through a photosensitive cell connected with a digital timer. The intensity of light was controlled such that normal rats showed a withdrawal response within 9-10 seconds. The test was performed at 5-minute intervals, and the results of two measurements were averaged.
  • the expression of Fos protein a pain-related neuron, was examined in the following manner.
  • the immunohistochemical staining of c-Fos protein in the spinal cord was executed. Animals were anesthetized with 5% isoflurane and perfused transcardically with calcium-free Tyrode's solution followed by Lana's fixative (4% paraformaldehyde, 0.2% picric acid, 0.1 M phosphate buffer, pH 6.9, TPBS). Immediately after the perfusion, spinal cords were isolated and post-fixed in the same fixative for 4 hours.
  • the spinal cords were cryoptotected in 30% sucrose (in PBS, pH 7.4). After the spinal cords were rapidly frozen with Siphon gas, the L3-L5 spinal segments were sectioned with a cryostat (Microm, Germany) to a thickness of 40 ⁇ m. Then, the sections were washed 6 times with TPBS for 5 minutes each wash. And then, they were quenched with 0.3% H 2 O 2 /TPBS to block the intrinsic peroxidase activity, and were allowed to react with 1% normal goat serum/ 0.3% triton X-IOO at room temperature for 1 hour to block non-specific reactions (preblock process).
  • the suspended sections were allowed to react with rabbit polyckonal antibodies to c-Fos (Calbiochem, 1 : 10,000) at 4 °C for 24 hours, and then washed 6 times with TPBS for 5 minutes each wash. Then, the sections were allowed to react with a goat anti-Rb IgG secondary antibody (Vector, 1% NGS/triton-X 100/TPBS, a 1 :200 dilution) at room temperature for 1 hour.
  • a goat anti-Rb IgG secondary antibody Vector, 1% NGS/triton-X 100/TPBS, a 1 :200 dilution
  • the sections were washed 6 times with TPBS for 5 minutes each wash and subjected to reacted with streptoavidin (avidin-biotin reaction, 0.3% tritons X/TPBS, a 1 :200 dilution) at room temperature for 1 hour, and then washed 6 times with TPBS for 5 minutes each wash.
  • streptoavidin avidin-biotin reaction, 0.3% tritons X/TPBS, a 1 :200 dilution
  • the expression of c-Fos protein in the sections was examined using 3-3 diamino-benzidine reaction (Sigma Chemicals, USA). Then, the sections were washed 6 times with TPBS for 5 minutes each wash, and the tissue sections were dehydrated with alcohol and cleared with xylene.
  • FIG. 10 The effect of the OE on the expression of Fos protein in the spinal cord after the induction of arthritis was evaluated as described above, and the evaluation results are shown in FIG. 10. As shown in FIG. 10, the Fos protein was observed less in the ibuprofen group (B) and the group (C) administered with the OE, as compared to the vehicle (A). Also, as shown in FIG. 10 and FIG.
  • FLI Fos-like immunoreactivity
  • the number of FLI neurons in both the right and left spinal cords was reduced in the superficial dorsal horn (SDH), the nucleus veins (NP) and the neck of dorsal horn (NECK). Also, the number of FLI neurons was further reduced in the NP site of the left spinal cord, as compared to the right spinal cord with induced arthritis (see FIG. 11). From the above results, it could be found that the OE not only reduced analgesic stimulation primarily caused by arthritis, but also effectively inhibited neurogenic stimulation caused by the transfer of arthritis to the left paw. This effect of inhibiting the activity of pain-related neurons was similar to that of the ibuprofen-treated group. This demonstrates again that the OE has an excellent analgesic effect.
  • the body weight at 21 days after the induction of arthritis was markedly reduced compared to the body weight at 9 days after induction of arthritis, and it is considered that this reduction in body weight is attributable not to a decrease in arthritis severity, but to gastrointestinal disorders resulting from a reduction in endogenous cyclooxygenase activity (Whittle, Fundam. Clin. Pharmacol, 17:301, 2003).
  • the body weight up to 21 days after induction of arthritis was not statistically significantly different from the body weight at 9 days after the induction of arthritis, and maintained the body weight at 9 days after the induction of arthritis. From the above results, it could be seen that the OE had no side effects on fundamental physiological phenomena such as body weight decrease, unlike ibuprofen showing anti-inflammatory effects similar to those of the inventive extract.
  • the anti-inflammatory and analgesic composition of the present invention is a material of natural origin and shows the same antiinflammatory and analgesic effect as that of synthetic material, ibuprofen, while the incidence of side effects thereof, such as causing disease in the gastrointestinal tract system, is low.
  • the inventive method for preparing the Oldenlandia diffusa extract has an advantage in that compounds having excellent anti-inflammatory and analgesic effects can be obtained from Oldenlandia diffusa in high yield through a simple process.
  • the inventive composition will be useful as health functional foods and medical drugs for anti-inflammation and pain relief against arthritis and the like.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

L'invention concerne une composition anti-inflammatoire et analgésique comprenant un extrait d'Oldenlandia diffusa contenant de l'acide ursolique et de l'acide oléanolique. La teneur en acide ursolique et en acide oléanolique de l'extrait d'Oldenlandia diffusa est de 80/95 % en poids, et le rapport acide ursolique : acide oléanolique est de 1:0,05/0,6.
PCT/KR2007/001785 2006-05-03 2007-04-12 Composition comprenant de l'acide ursolique et de l'acide oléanolique destinée à améliorer un traitement contre l'arthrite WO2007126221A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2009506406A JP2009534374A (ja) 2006-05-03 2007-04-12 ウルソール酸及びオレアノール酸を含有する白花蛇舌草抽出精製物を含む消炎または鎮痛用の組成物
KR1020087023992A KR101084105B1 (ko) 2006-05-03 2007-04-12 어솔릭산 및 올레아놀릭산을 함유하는 관절염 예방 및치료용 조성물

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2006-0039925 2006-05-03
KR20060039925 2006-05-03

Publications (1)

Publication Number Publication Date
WO2007126221A1 true WO2007126221A1 (fr) 2007-11-08

Family

ID=38655710

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2007/001785 WO2007126221A1 (fr) 2006-05-03 2007-04-12 Composition comprenant de l'acide ursolique et de l'acide oléanolique destinée à améliorer un traitement contre l'arthrite

Country Status (3)

Country Link
JP (1) JP2009534374A (fr)
KR (1) KR101084105B1 (fr)
WO (1) WO2007126221A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100112097A1 (en) * 2008-11-03 2010-05-06 Jong Hyun Nam Pharmaceutical composition for preventing and treating cancer and health food containing the same for preventing and treating cancer
JP2010229083A (ja) * 2009-03-27 2010-10-14 Noevir Co Ltd 抗老化剤、保湿剤、美白剤、抗酸化剤、抗炎症剤、皮膚外用剤
CN101418325B (zh) * 2008-12-03 2012-04-04 王�琦 桦褐孔菌胞内外混合多糖及其制备方法和药物用途
CN102670768A (zh) * 2012-05-15 2012-09-19 宋协勘 一种治疗急性阑尾炎的中药
ITGE20110041A1 (it) * 2011-04-12 2012-10-13 Ct Di Sperimentazione Ed Assist Enza Agricola Metodo di ottenimento di acido carnosico e triterpeni, come composti puri o come fitocomplessi arricchiti, da piante della famiglia delle lamiaceae
WO2013068626A1 (fr) * 2011-11-10 2013-05-16 Consejo Superior De Investigaciones Científicas (Csic) Triterpènes pentacycliques à utiliser dans la prévention ou le traitement de la myocardite aiguë ou subaiguë
CN105029395A (zh) * 2014-04-15 2015-11-11 四川万安石斛产业开发有限公司 一种增强免疫的食品、保健品或药物组合物
US20160106790A1 (en) * 2013-06-13 2016-04-21 Altera International, Ltd. Methods of improving reproductive and respiratory health
CN108434131A (zh) * 2018-03-01 2018-08-24 南昌大学 白花蛇舌草提取物在制备治疗炎症疾病药物中的应用
CN113185567A (zh) * 2021-05-12 2021-07-30 张洪胜 一种治疗类风湿关节炎熊果酸衍生物及其制备方法
CN114159406A (zh) * 2021-09-15 2022-03-11 山东农业大学 一种复合抗炎纳米颗粒及其制备方法与应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102271835B1 (ko) 2014-11-19 2021-07-01 주식회사 엘지생활건강 모발 강화용 화장료 조성물
JP2017109942A (ja) * 2015-12-15 2017-06-22 日本製粉株式会社 オレアナン型トリテルペンを有効成分として含有するトレーニング機器を使用しないレジスタンストレーニングによる膝関節機能改善作用および骨格筋機能増強作用を促進させる為の組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030064107A (ko) * 2002-01-25 2003-07-31 주식회사 태평양 백화사설초 추출물을 함유하는 피부 외용제 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61268648A (ja) * 1985-05-22 1986-11-28 Rooto Seiyaku Kk オレアノ−ル酸の製造方法
JP2002284696A (ja) * 2001-03-28 2002-10-03 Doi Keiko ウイルス、真菌その他の菌性疾患の治療方法
JP2004175762A (ja) * 2002-11-28 2004-06-24 Tokio Yazaki 抗がん剤
CA2571796C (fr) * 2004-07-01 2009-06-02 E-L Management Corp. Compositions cosmetiques et procede a base d'un agent bronzant et d'acide ursolique encapsule dans un liposome

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030064107A (ko) * 2002-01-25 2003-07-31 주식회사 태평양 백화사설초 추출물을 함유하는 피부 외용제 조성물

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KIM Y.H.: "Studies on the constituents of Oldenlandia diffusa", KOREAN J. MEDICINAL CROP. SCI., vol. 3, no. 2, 1995, pages 91 - 95, XP053019303 *
LIU J.: "Pharmacology of oleanolic acid and ursolic acid", J. ETHNOPHARMACOL., vol. 49, no. 2, 1995, pages 57 - 68, XP002571740, DOI: doi:10.1016/0378-8741(95)90032-2 *
TAPONDJOU L.A. ET AL.: "In vivo anti-nociceptive and anti-inflammatory effect of the two triterpenes, ursolic acid and 23-hydroxyursolic acid, from Cussonia bancoensis", ARCH. PHARM. RES., vol. 26, no. 2, 2003, pages 143 - 146 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100112097A1 (en) * 2008-11-03 2010-05-06 Jong Hyun Nam Pharmaceutical composition for preventing and treating cancer and health food containing the same for preventing and treating cancer
CN101418325B (zh) * 2008-12-03 2012-04-04 王�琦 桦褐孔菌胞内外混合多糖及其制备方法和药物用途
JP2010229083A (ja) * 2009-03-27 2010-10-14 Noevir Co Ltd 抗老化剤、保湿剤、美白剤、抗酸化剤、抗炎症剤、皮膚外用剤
ITGE20110041A1 (it) * 2011-04-12 2012-10-13 Ct Di Sperimentazione Ed Assist Enza Agricola Metodo di ottenimento di acido carnosico e triterpeni, come composti puri o come fitocomplessi arricchiti, da piante della famiglia delle lamiaceae
ES2407089A1 (es) * 2011-11-10 2013-06-11 Consejo Superior De Investigaciones Científicas (Csic) Triterpenos pentacíclicos para utilizar en la prevención o tratamiento de la miocarditis aguda o subaguda
WO2013068626A1 (fr) * 2011-11-10 2013-05-16 Consejo Superior De Investigaciones Científicas (Csic) Triterpènes pentacycliques à utiliser dans la prévention ou le traitement de la myocardite aiguë ou subaiguë
CN102670768A (zh) * 2012-05-15 2012-09-19 宋协勘 一种治疗急性阑尾炎的中药
US20160106790A1 (en) * 2013-06-13 2016-04-21 Altera International, Ltd. Methods of improving reproductive and respiratory health
US11241464B2 (en) * 2013-06-13 2022-02-08 Altera International, Ltd. Methods of improving reproductive and respiratory health
CN105029395A (zh) * 2014-04-15 2015-11-11 四川万安石斛产业开发有限公司 一种增强免疫的食品、保健品或药物组合物
CN108434131A (zh) * 2018-03-01 2018-08-24 南昌大学 白花蛇舌草提取物在制备治疗炎症疾病药物中的应用
CN113185567A (zh) * 2021-05-12 2021-07-30 张洪胜 一种治疗类风湿关节炎熊果酸衍生物及其制备方法
CN114159406A (zh) * 2021-09-15 2022-03-11 山东农业大学 一种复合抗炎纳米颗粒及其制备方法与应用

Also Published As

Publication number Publication date
KR101084105B1 (ko) 2011-11-16
KR20080105140A (ko) 2008-12-03
JP2009534374A (ja) 2009-09-24

Similar Documents

Publication Publication Date Title
WO2007126221A1 (fr) Composition comprenant de l'acide ursolique et de l'acide oléanolique destinée à améliorer un traitement contre l'arthrite
KR101613693B1 (ko) 괭생이 모자반 추출물을 유효성분으로 포함하는 아토피성 피부질환 예방 또는 치료용 조성물 및 이의 제조방법
WO2005115427A1 (fr) Composition medicinale a base de plantes destinee a traiter l'obesite et son procede de preparation
WO2007007993A1 (fr) Composition pharmaceutique destinee a la prevention et au traitement de maladies du foie contenant un extrait de lonicera caerulea l. var. edulis
EP3025721B1 (fr) Composition pharmaceutique pour la prévention ou le traitement de l'asthme comprenant un extrait de pistacia weinmannifolia j. poiss. ex franch ou une fraction de celui-ci
KR100686260B1 (ko) 장구채 추출물을 포함하는 간 기능 개선 및 간질환 치료용 조성물
US20150335699A1 (en) Composition for Prevention or Treatment of Acute Renal Failure Including Herbal Extract or Fraction Thereof as Active Ingredient
KR101016837B1 (ko) 금은화 추출물을 유효성분으로 함유하는 관절염의 예방 및치료용 조성물
US11484562B2 (en) Composition for preventing or treating obesity comprising natural mixture extracts
KR20140108104A (ko) 한인진 및 울금의 복합추출물을 유효성분으로 포함하는 비만 관련 질환의 예방, 억제 또는 치료용 조성물
KR20220067467A (ko) 몰로키아 추출물을 유효성분으로 포함하는 알코올성 간 손상 개선, 예방 또는 치료용 조성물
KR20040080640A (ko) 항통풍활성을 갖는 개다래 추출물을 함유하는 약학조성물
KR100760386B1 (ko) Ａｃｐ 혼합생약 추출물을 포함하는 관절염의 예방 및 치료용 조성물
KR102627108B1 (ko) 벌나무 추출물 및 버섯 추출물의 혼합물을 유효성분으로 포함하는 비알코올성 지방간의 예방, 개선 또는 치료용 약학적 조성물 및 이의 제조방법
EP2992890B1 (fr) Composition pharmaceutique pour le traitement des maladies inflammatoires chronique de l' intestin
KR20150040068A (ko) 한련초 추출물을 유효성분으로 함유하는 대장염의 예방, 개선 또는 치료를 위한 조성물
KR101620160B1 (ko) 백출 속 및 탱자를 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 조성물
WO2021172726A1 (fr) Composition alimentaire fonctionnelle de santé contenant un extrait de sanguisorba officinalis l.
KR102019974B1 (ko) 감초 및 노랑민들레 추출물을 유효성분으로 함유하는 알코올성 위장관질환의 예방, 개선 또는 치료용 조성물
US10548936B2 (en) Method for reducing weight
KR20230149568A (ko) 고량강 추출물을 유효성분으로 포함하는 알러지성 호흡기 질환의 예방, 개선 또는 치료용 조성물
KR20060035921A (ko) 한약재와 배 추출물을 배합한 항당뇨 식품 조성물 및 그의제조방법
KR101588229B1 (ko) 마치현 추출물을 유효성분으로 함유하는 급성 췌장염의 예방, 개선 또는 치료를 위한 조성물
KR20220122877A (ko) 블랙커런트 열수 추출물을 포함하는 비알코올성 지방간 질환의 예방, 개선 또는 치료용 조성물
KR20230149562A (ko) 조협 추출물을 유효성분으로 포함하는 알러지성 호흡기 질환의 예방, 개선 또는 치료용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07745948

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009506406

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020087023992

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07745948

Country of ref document: EP

Kind code of ref document: A1